Blurbs

Guardant Health (GH) Receives a Buy from SVB Securities

In a report issued on August 2, Puneet Souda from SVB Securities maintained a Buy rating on Guardant Health (GHResearch Report). The company’s shares closed last Thursday at $51.09.

According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.6% and a 40.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $91.67 average price target, a 78.3% upside from current levels. In a report issued on July 20, Bank of America Securities also maintained a Buy rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Guardant Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $96.1 million and GAAP net loss of $123 million. In comparison, last year the company earned revenue of $78.67 million and had a GAAP net loss of $110 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Read More on GH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos